Human papillomavirus type 16 E6 messenger RNA (HPV16 E6 mRNA)

Human papillomavirus type 16 (HPV16) E6 messenger RNA (mRNA) is the transcript responsible for the synthesis of the E6 oncoprotein, a major driver of oncogenesis in high-risk HPV infections. The E6 protein functions primarily by recruiting the host E3 ubiquitin ligase E6AP to target the tumor suppressor protein p53 for proteasomal degradation, thereby inhibiting apoptosis and promoting uncontrolled cell proliferation (Vande Pol & Klingelhutz, 2013; Scheffner et al., 1993). Because the maintenance of the malignant phenotype in HPV-positive cancer cells is dependent on the continuous expression of E6, this mRNA is a high-priority target for therapeutic intervention (Goodwin & DiMaio, 2000). Experimental strategies to target HPV16 E6 mRNA include the use of small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and CRISPR/Cas9 systems designed to degrade the transcript or inhibit its translation (Walboomers et al., 1999). These approaches aim to restore p53 levels, leading to the induction of senescence or apoptosis in malignant cells. Clinically, the presence of HPV16 E6 mRNA serves as a critical biomarker for identifying high-grade cervical lesions and assessing the risk of progression to invasive cancer (Heideman et al., 2008). Unlike DNA testing, mRNA testing provides information on the transcriptional activity of the virus, which is more closely associated with oncogenic potential. Challenges in targeting this molecule include the efficient delivery of nucleic acid-based drugs to tumor sites and the potential for off-target effects in host tissues (Vande Pol & Klingelhutz, 2013).

Other names

HPV16 E6 transcriptHuman papillomavirus 16 E6 mRNAHPV-16 E6 mRNAHPV16 E6/E7 mRNA

RNA interference (RNAi) or antisense-mediated degradation of the mRNA transcript, leading to reduced levels of the E6 oncoprotein and subsequent restoration of p53 levels.